Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,331 across all filing types
Latest filing 2019-04-09 Regulatory Filings
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Update on BLCT with Hexvix® from The Australian Government Department of Health
Regulatory Filings Classification · 100% confidence The document is a press release from Photocure ASA announcing an update regarding reimbursement for their product Hexvix® from the Australian Government Department of Health, effective May 1, 2019. It details the establishment of new Medical Benefit Schedule (MBS) items. This type of announcement, which communicates a specific operational or regulatory update (reimbursement/pricing change) that is not a full financial report (10-K, IR), management change (MANG), or dividend declaration (DIV), fits best under a general regulatory or operational announcement category. Since it is not a standard earnings release (ER) or a formal legal proceeding report (LTR), and it is a specific announcement of a regulatory/governmental decision impacting operations, it is classified as a general Regulatory Filing (RNS) as it serves as a broad regulatory update/announcement that doesn't fit the more specific categories like CAP, DVA, or DLST. The document length is relatively short (3586 chars), but it contains the full substance of the announcement, not just a pointer to another report, so RPA is less appropriate than RNS for this type of specific regulatory news.
2019-04-09 English
Photocure: New Data on Cysview® to be presented at the upcoming AUA 2019 Annual Meeting
AGM Information Classification · 95% confidence The document is a press release from Photocure ASA dated April 8, 2019, announcing that new data regarding their product Cysview® will be presented at the upcoming American Urological Association (AUA) 2019 Annual Meeting. This is an announcement about participation in a medical/industry conference, detailing presentation schedules and booth information. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is an announcement related to company activities and presentations, and does not fit the specific categories like AGM-R, ER, or IR, it falls best under the general 'Regulatory Filings' (RNS) category as a general corporate announcement, or potentially a specialized Investor Presentation (IP) if it were the presentation itself, but here it is an announcement *about* presentations. Given the options, RNS serves as the most appropriate general announcement category for non-standard corporate news that isn't a core financial report or management change.
2019-04-08 English
Patients want Blue Light Cystoscopy
Regulatory Filings Classification · 85% confidence The document text is very short (824 characters) and appears to be a brief news item or press release snippet discussing a survey result regarding patient preference for a specific medical procedure (Blue Light Cystoscopy with Cysview). It does not contain the structure, headers, or detailed financial data associated with 10-K, IR, ER, or AR. Since it is a short announcement/update that doesn't fit the specific categories like AGM-R, MANG, DIRS, DIV, etc., and seems to be general company/product news, the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general announcement category for miscellaneous regulatory or news items that don't fit elsewhere.
2019-03-28 English
Hexvix® / Cysview® with Flexible Cystoscopy improves Bladder Cancer detection. Data presented at the EAU congress in Barcelona.
Regulatory Filings Classification · 95% confidence The document is explicitly introduced as a press release ('Oslo, Norway March 19, 2019, Photocure ASA (PHO:OSE), is pleased to announce...'). It details positive clinical data presentation at a major medical congress (EAU) regarding their product Hexvix® / Cysview®. This format—announcing recent operational or clinical news via a press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it focuses on announcing recent positive developments and data presentation, it aligns best with an Earnings Release (ER) which often includes key operational highlights, or RNS as a general announcement. Given the content is focused on clinical/product news rather than quarterly financial figures, RNS is a strong candidate, but ERs frequently contain such operational updates alongside or instead of pure financial numbers. However, since the core function here is announcing a specific event (data presentation) and key takeaways, and it is not explicitly labeled as an 'Earnings Release', the most appropriate general category for a non-standard, timely announcement is Regulatory Filings (RNS). If the document were purely focused on financial results, ER would be better. Since it's a general announcement of clinical/business progress, RNS is the safest fit as a regulatory disclosure.
2019-03-19 English
Photocure ASA: Hexvix® /Cysview® with Flexible Cystoscopy improves Bladder Cancer detection. Data presented at the EAU congress in Barcelona.
Regulatory Filings Classification · 100% confidence The document is a press release from Photocure ASA dated March 19, 2019, announcing that data regarding their product Hexvix®/Cysview® was presented at the European Association of Urology (EAU) congress. It details clinical findings, quotes management, and provides background information on bladder cancer and the product. This format—a news announcement highlighting recent developments, data presentations, or business updates that are not a full statutory report (like 10-K or IR) or a formal earnings release (ER)—most closely aligns with a general regulatory announcement or news release. Since it is not a formal financial report, a proxy statement, or a specific transaction notice, the most appropriate general category is Regulatory Filings (RNS), which serves as a broad category for non-standard announcements. It is not an Earnings Release (ER) as it focuses on clinical data presentation, not period financial results.
2019-03-19 English
Photocure ASA: Results for the fourth quarter of 2018
Earnings Release Classification · 98% confidence The document is explicitly titled "FOURTH QUARTER REPORT 2018" and contains detailed financial tables summarizing performance for Q4 2018 and the Full Year (FY) 2018, comparing them against 2017 figures. It includes sections like 'Highlights for fourth quarter and full year 2018', 'Operational review', and 'Financial review' with comprehensive income statement data (revenues, EBITDA, EBIT, Net Profit/loss). This structure is characteristic of a comprehensive periodic financial report covering a period shorter than a full year, which aligns with the definition of an Interim / Quarterly Report (IR). It is not an Earnings Release (ER) because it is a full report, not just highlights, and it is not a 10-K as it covers only a quarter/year-to-date period, not the full fiscal year in the context of a major regulatory filing. Q4 2018
2019-02-27 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.